Refining Genotypes and Phenotypes in KCNA2-Related Neurological Disorders

Jan H. Döring 1, Julian Schröter 1, Jerome Jüngling 2, Saskia Biskup 2,3, Kerstin A. Klotz 4,5, Thomas Bast 6,7, Tobias Dietel 7, G. Christoph Korenke 8, Sophie Christoph 8, Heiko Brennenstuhl 9, Guido Rubboli 10, Rikke S. Møller 10,11, Gaetan Lesca 12, Yves Chaix 13, Stefan Kölker 9, Georg F. Hoffmann 9, Johannes R. Lemke 14,15 and Steffen Syrbe 1,*

1 Division of Paediatric Epileptology, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany; jan.doering@uni-heidelberg.de (J.H.D.); julian.schroeter@med.uni-heidelberg.de (J.S.)
2 Praxis für Humangenetik Tübingen, 72076 Tübingen, Germany; jerome.juengling@humangenetik-tuebingen.de (J.J.); saskia.biskup@humangenetik-tuebingen.de (S.B.)
3 CEGAT GmbH, 72076 Tübingen, Germany
4 Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; kerstin.alexandra.klotz@uniklinik-freiburg.de
5 Department of Epileptology, Medical Center, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany
6 Medical Faculty, University Hospital Freiburg, 79085 Freiburg, Germany; tbast@diakonie-kork.de
7 Epilepsy Center Kork, Medical Faculty of the University of Freiburg, 77694 Kehl, Germany; tdietel@diakonie-kork.de
8 Department of Neuropediatrics, University Children’s Hospital, Klinikum Oldenburg, 26133 Oldenburg, Germany; korenke.georg-christoph@klinikum-oldenburg.de (G.C.K.);
christoph.sophie@klinikum-oldenburg.de (S.C.)
9 Division of Paediatric Neurology and Metabolic Medicine, Centre for Paediatric and Adolescent Medicine, University Hospital, 69120 Heidelberg, Germany; heiko.brennenstuhl@med.uni-heidelberg.de (H.B.); Stefan.Koelker@med.uni-heidelberg.de (S.K.); Georg.Hoffmann@med.uni-heidelberg.de (G.F.H.)
10 Danish Epilepsy Centre, 4293 Dionalund, Denmark; guru@filadelfia.dk (G.R.); rimo@filadelfia.dk (R.S.M.)
11 Department of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark
12 Department of Medical Genetics, Lyon University Hospital, University of Lyon, 69100 Lyon, France; gaetan.lesca@chu-lyon.fr
13 Pediatric Neurology Unit, Children’s Hospital, Purpan University Hospital, 31300 Toulouse, France; CHAIX.Y@chu-toulouse.fr
14 Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig, Germany; Johannes.Lemke@medizin.uni-leipzig.de
15 Center for Rare Diseases, University of Leipzig Medical Center, 04103 Leipzig, Germany
* Correspondence: steffen.syrbe@med.uni-heidelberg.de; Tel.: +49-6221-56-8228

Abstract: Pathogenic variants in KCNA2, encoding for the voltage-gated potassium channel Kv1.2, have been identified as the cause for an evolving spectrum of neurological disorders. Affected individuals show early-onset developmental and epileptic encephalopathy, intellectual disability, and movement disorders resulting from cerebellar dysfunction. In addition, individuals with a milder course of epilepsy, complicated hereditary spastic paraplegia, and episodic ataxia have been reported. By analyzing phenotypic, functional, and genetic data from published reports and novel cases, we refine and further delineate phenotypic as well as functional subgroups of KCNA2-associated disorders. Carriers of variants, leading to complex and mixed channel dysfunction that are associated with a gain- and loss-of-potassium conductance, more often show early developmental abnormalities and an earlier onset of epilepsy compared to individuals with variants resulting in loss- or gain-of-function. We describe seven additional individuals harboring three known and the novel KCNA2 variants.

By analyzing phenotypic, functional, and genetic data from published reports and novel cases, we refine and further delineate phenotypic as well as functional subgroups of KCNA2-associated disorders. Carriers of variants, leading to complex and mixed channel dysfunction that are associated with a gain- and loss-of-potassium conductance, more often show early developmental abnormalities and an earlier onset of epilepsy compared to individuals with variants resulting in loss- or gain-of-function. We describe seven additional individuals harboring three known and the novel KCNA2 variants p.(Pro407Ala) and p.(Tyr417Cys). The location of variants reported here highlights the importance of the proline(405)–valine(406)–proline(407) (PVP) motif in transmembrane domain S6 as a mutational hotspot. A novel case of self-limited infantile seizures suggests a continuous clinical spectrum of KCNA2-related disorders. Our study provides further insights into the clinical spectrum, genotype–phenotype correlation, variability, and predicted functional impact of KCNA2 variants.
Keywords: voltage-gated potassium channel; \( K_v 1.2 \); shaker; epileptic encephalopathy; epilepsy; ataxia

1. Introduction

Potassium channels are involved in many vital processes such as neuronal excitability, neurotransmitter release, and cellular osmoregulation [1,2]. KCNA2, encoding for the voltage-gated potassium channel subfamily A member 2 (\( K_v 1.2 \), OMIM * 176262) is a member of the shaker-like delayed rectifier potassium channel family [3]. It is predominantly expressed in axons and presynaptic terminals of the central nervous system [4,5]. Homo- or heterotetramers formed by \( \alpha \)-subunits containing variable proportions of \( K_v \)-subfamily members contribute to functional channel characteristics [6]. \( K_v 1.2 \) consists of six transmembrane segments (S1–S6) forming the voltage-sensing domain (S4) and the ion-conducting pore (S5-S6) with its selectivity filter localized in the pore loop [7,8]. The C-terminal and N-terminal cytosolic domains are less conserved and regulate tetramerization and the association to modifying subunits [9,10]. Several antibody-mediated neurological diseases in children and adults have been linked to proteins associated with \( K_v 1 \) channel components, such as leucine-rich glioma-inactivated 1, contactin-associated protein 2, and particularly \( K_v 1 \) channel subunits [11,12].

In 2015, pathogenic de novo variants in KCNA2 were first described in six individuals with early-onset severe epilepsy, cognitive impairment, and ataxia [13]. Two phenotypically distinct epilepsy syndromes were delineated correlating with gain-of-function (GOF) and loss-of-function (LOF) changes of the net potassium current of \( K_v 1.2 \) [13,14]. The recurrent KCNA2 variant c.881G > A, leading to an amino-acid exchange at position 294 within the voltage sensing domain, was identified in individuals with hereditary spastic paraplegia (HSP) as an additional phenotype [15]. In 2017, novel and previously reported individuals were summarized into three distinct functional and clinical subgroups of \( K_v 1.2 \) dysfunction: GOF, LOF, and a mixed dysfunctional type (GOF/LOF) [16].

In this study, we present additional individuals with known and novel variants in KCNA2. We reevaluate phenotypic, functional, and genetic data from all published cases to refine and further delineate the assumed phenotypic and functional subgroups. We analyze the genetic distribution of all known pathogenic and likely pathogenic variants in KCNA2 and predict the functional impact of all possible missense variations in KCNA2.

2. Results

We identified 115 individuals with pathogenic and likely pathogenic (P/LP) KCNA2 variants from 28 publications (78 cases) and ClinVar database entries (37 cases). Additionally, we report clinical data from seven novel cases, six individuals with P and LP KCNA2 variants, and one individual with a VUS. After the exclusion of all individuals without sufficient clinical information, we included 76 of 115 cases into further analyses (see Section 4).

In 40 individuals, variants occurred de novo, while 17 segregated with the disease in the family. In 21 cases, information on inheritance was unavailable. Thirty different alterations of KCNA2 are on record to date, with 26 single-nucleotide variants (SNV), one in-frame deletion, and three different deletions (Tables 1 and 2).
### Table 1. KCNA2 variants from published clinical reports.

| cDNA Change | Protein Change | Functional Consequence | Phenotype | Number of Patients | Reference |
|-------------|----------------|------------------------|-----------|--------------------|-----------|
| **heterozygous variants:** | | | | | |
| **missense** | | | | | |
| c.469G > A | p.(Glu157Lys) | GOF | epileptic encephalopathy | 1 | [16] |
| c.676G > A | p.(Glu226Lys) | no data | epilepsy, childhood-onset | 1 | [17] |
| c.817T > C | p.(Ile267Thr) | LOF | epileptic encephalopathy | 1 | [13,16] |
| c.897G > T | p.(Leu299Arg) | GOF/LOF | epileptic encephalopathy | 2 | [16,18,19] |
| c.878T > A | p.(Leu293His) | GOF/LOF | epileptic encephalopathy | 1 | [16] |
| c.921G > C | p.(Val307Met) | no data | developmental and epileptic encephalopathy | 3 | [21-23] |
| c.980G > A | p.(Arg297Gln) | GOF | ataxia & myoclonic epilepsy | 15 | [3,13,14,16,24-29] |
| c.894G > T | p.(Leu298Phe) | GOF | epileptic encephalopathy | 1 | [13,16] |
| c.995C > T | p.(Thr328Ile) | no data | epilepsy, mild ataxia | 1 | [30] |
| c.971G > C | p.(Ser324Thr) | no data | epilepsy, drug-resistant | 1 | [31] |
| c.982T > G | p.(Leu328Val) | GOF/LOF | epileptic encephalopathy | 2 | [16,32] |
| c.1070G > A | p.(Gln357Arg) | no data | developmental and epileptic encephalopathy | 8 | [16,26,33-35] |
| c.1120A > G | p.(Thr374Ala) | GOF/LOF | epileptic encephalopathy, early onset | 1 | [16,16,23,34,37,38] |
| c.1192G > T | p.(Gly398Cys) | LOF | epileptic encephalopathy | 1 | [16] |
| c.1195G > A | p.(Val399Met) | no data | epilepsy, mild ataxia | 1 | [23] |
| c.1202C > T | p.(Thr401Ile) | no data | epileptic encephalopathy | 1 | [36] |
| c.1214C > T | p.(Pro405Leu) | LOF | epileptic encephalopathy | 14 | [13,16,23,34,37,38] |
| c.1223T > C | p.(Val408Ala) | no data | Rett-like syndrome with infantile onset seizures | 1 | [39] |
| **truncating** | | | | | |
| c.637C > T | p.(Gln213*) | LOF | epileptic encephalopathy | 1 | [16] |
| c.193C > T | p.(Arg65*) | predicted LOF | epilepsy | 1 | [17] |
| c.1265_1266delAG | p.(Glu422Glyfs*21) | predicted LOF | epileptic encephalopathy | 1 | [26] |
| **in-frame deletion** | | | | | |
| c.765_773del | p.(Met255_Ile257del) | LOF | episodic ataxia & pharmacoresponsive epilepsy | 7 | [3] |
| **deletion** | | | | | |
| c.11060681_11139713del~788kb | | no data | generalized epilepsy | 1 | [40] |
| **homozygous variants:** | | | | | |
| c.193C > T | p.(Arg65*) | no data | intellectual disability, autosomal-recessive | 4 | [41] |

GOF: gain-of-function effects, LOF: loss-of-function effects compared to wild-type channels; all variants are described according to the transcript NM_004974.3.

### Table 2. Variants of KCNA2 reported in ClinVar.

| cDNA Change | Protein Change | Interpretation | Phenotype | Number of Reported Patients |
|-------------|----------------|----------------|-----------|-----------------------------|
| **missense** | | | | | |
| c.788T > C | p.(Ile263Thr) | LP | epileptic encephalopathy | 2 |
| c.869T > C | p.(Leu299Pro) | LP | epileptic encephalopathy | 1 |
| c.881G > A | p.(Arg294His) | LP | epileptic encephalopathy | 4 |
| c.894G > T | p.(Leu298Phe) | LP | epileptic encephalopathy | 2 |
| c.959C > T | p.(Thr320Ile) | LP | epileptic encephalopathy | 1 |
| c.995C > T | p.(Thr328Ile) | LP | epileptic encephalopathy | 1 |
| c.1013G > A | p.(Gly338Glu) | LP | not provided | 1 |
| c.1219G > T | p.(Pro405Leu) | LP | epileptic encephalopathy | 8 |
| c.1219C > G | p.(Pro407Ala) | LP | not provided | 2 |
| c.1223T > C | p.(Val408Ala) | P | epileptic encephalopathy | 1 |
| **truncating** | | | | | |
| c.298C > T | p.(Arg100*) | LP | epileptic encephalopathy | 1 |
| **deletion** | | | | | |
| g.(?_110593873)_(110604802_?)del | | P | epileptic encephalopathy | 1 |

all variants are described using the transcript NM_004974.3; LP: likely pathogenic; P: pathogenic.
2.1. Novel Cases with KCNA2 Variants in this Study

Data from seven previously unpublished cases with known pathogenic (n = 5) and novel variants (n = 2) in KCNA2 were ascertained. Genetic and phenotypic data are summarized in Table 3. The localization and structural consequence of the novel missense variant p.(Tyr417Cys) is depicted in Figure 1. Furthermore a comparison of the wild-type proline(405)–valine(406)–proline(407) (PVP) motif and changes by the novel variant p.(Pro407Ala) and the known variant p.(Pro405Leu) are shown.

Figure 1. Localization of three identified missense variants in the Kv1.2 channel. Three-dimensional (3D) protein structure of the Kv1.2 channel shown as a ribbon model. (A) Lateral overview of the channel tetramer (turquoise) and three potassium ions localized in the channel pore (spheres, gray). The residues Pro405, Pro407, and Tyr417 are shown in stick representation (red). The S4–S5 linker is highlighted in orange. (B) Close-up view of residue Tyr417 and (C) the mutated residue Cys417 (red sticks), in context with the S4–S5 linker regions of the same and neighboring channel subunits, respectively (orange). (D–F) Close-up views of the proline(405)–valine(406)–proline(407) (PVP) motif (red sticks; (D)) as well as the amino acid substitutions Leu405 (E) and Ala407 (F) of the corresponding proline residues. The PVP motif interacts with the S4–S5 linker, and both prolines of this symmetric motif (D) are important for channel gating. The substitution of Pro405 (E) and Pro407 (F) disrupts its symmetry and structure, likely impairing interactions with S4–S5 during gating-related conformational changes. All three substitutions are located in the S6 helix and in proximity to the S4–S5 linkers, which is suggestive for the probable affection of associated interactions leading to altered channel gating.
Table 3. Genetic and clinical characteristics of novel cases with KCNA2 variants.

| Case | 1            | 2            | 3            | 4            | 5            | 6            | 7            |
|------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| cDNA Change | c.1250A > G  | c.1219C > G  | c.1214C > T  | c.1214C > T  | c.890G > A   | c.881G > A   | c.881G > A   |
| Protein Change | p.(Tyr417Cys) | p.(Pro407Ala) | p.(Pro405Leu) | p.(Pro405Leu) | p.(Arg297Gln) | p.(Arg294His) | p.(Arg294His) |
| Inheritance | parental     | de novo      | de novo      | de novo      | de novo      | Familial (sister of #7) | Familial (brother of #6) |
| Age at inclusion/Gender | 3 y/m | 3 y/f | 8 y/f | 2 y/m | 9 y/m | 8 y/f | 8 y/m |
| Development before seizure onset | normal | na | normal | normal | normal | mildly delayed motor development | delayed speech and motor development |
| Epilepsy onset (months) | 7.5 | 0.25 | 21 | 7 | 8 | 72 | 24 |
| Seizure types | bilateral tonic-clonic generalized onset tonic and hypomotor seizures with cyanosis | prolonged febrile motor seizure | prolonged focal motor onset seizures and bilateral tonic-clonic seizures, febrile seizures, postictal hemiplegia | generalized onset bilateral tonic-clonic seizures, atypical absences from 3y3m | febrile seizures; generalized onset myoclonic and absence seizures, status epilepticus | febrile seizures; focal and generalized onset, absence seizures, myoclonic and tonic seizures, status epilepticus |
| Seizure outcome | seizure free at 10 months | seizure-free at 2 years | ongoing | seizure free at 2 years | ongoing | ongoing | ongoing |
| ID | normal | severe ID | moderate ID | normal | learning disability | mild ID | moderate ID |
| Movement disorders | no | no | episodic ataxia | ataxia | multifoil spikes and polyseps with typical motor seizures | ataxia, tremor, worsening on VPA |
| EEG features | normal at 3y multifocal spikes and reduced physiologic sleep characteristics | multifocal spikes in both centro-temporal regions, evolving to hemi-CSWS during follow-up | multifocal spikes, activation during sleep | na | multifocal spikes and polyspikes frontal photoparoxysmal reaction, 3–4 Hz spike waves | generalized slowing, activation of epileptiform activity by photostimulation, multifocal spikes, 3–4 Hz spike waves |
| Magnetic resonance imaging | normal | normal | left sided hippocampal sclerosis | normal | cystic lesion subcortical frontal left DNET | cerebellar atrophy (vermis) |
| Additional findings | SGA/dystrophy | dystharia | polydactyly left | dystharia and stuttering | muscular hypotonia | dystrophy, microcephaly, muscular hypotonia |
| Comments | reported in ClinVar | reported in ClinVar |

ID: intellectual disability, n/a: not available; CSWS: continuous spikes and waves during sleep. CSWS was defined by a Spike-Wave-Index (SWI) of at least 85% in an epoch of at least 10 min duration after onset of alpha attenuation or clinical signs of sleep; DNET: dysembryoblastic neuroectodermal tumor; SGA: small for gestational age; na: not available; f: female; m: male; y: years.
2.2. Clinical Characteristics of Individuals with Reported and Novel KCNA2 Variants

Mean age at inclusion and publication was 17 years (median age 10 years, range 0–81 years). No individual had died until the last reported study visit. Nearly all (91%) reported cases developed seizures. Mean age at seizure onset was 13 months (median age 8 months, range 0–156 months). In total, 41 male and 33 female individuals were included (three cases with missing information). No relevant differences in gender distribution on clinical manifestation or genotype were observed. Seven individuals were reported as not having seizures at all, of whom five harbor the variant p.(Arg294His) associated with hereditary spastic paraplegia and ataxia (HSP) [15,20] and two harbor the homozygous variant p.(Arg65*) associated with familial intellectual disability [41]. Associated movement and motor disorders were reported in 61/64 cases (95%), with ataxia in 64% of reported cases, tremor in 23%, and increased muscle tone (spasticity), in 16%. Febrile seizures were described in 28% (21/76) of cases. 30% (21/69) of the patients achieved seizure control (missing data in 11 cases). Of the cases with available data, most individuals (82%, 59/72) show intellectual disability of various severity. Thirteen individuals were reported with a normal cognitive development, including all five cases harboring the p.(Met255_Ile257del) deletion [3]. Cranial magnetic resonance imaging (available in 58 cases) was abnormal in 23 cases (40%), with cerebellar atrophy being most commonly reported (n = 18).

2.3. Phenotypic Features of Reported and Novel Patients, Grouped According to Known Functional Consequences on Kv1.2

Of all reported alterations of KCNA2, electrophysiological channel characterization has been available in 13/30 (43%) variants. Six different electrophysiological LOF variants in KCNA2 have been described [3,13,15,16,20], three different KCNA2 variants caused GOF in cellular expression systems [3,13,14,16,24–26] and four variants were reported having mixed functional effects (GOF/LOF) on mutated channels [16,19,34,35]. Of all reported and novel individuals, 61/76 (80%) harbored variants that have been electrophysiologically characterized. As proposed before, we grouped patients according to these known functional consequences on Kv1.2 for phenotypic comparison (Table 4).

Compared to individuals with a mixed dysfunctional type (LOF/GOF), individuals with LOF variants showed better development before seizure onset (p = 0.012), later onset of epilepsy (p = 0.033), more favorable epilepsy outcome (seizure-free) (p = 0.014), and less severe intellectual disability (p = 0.029). Compared to individuals with LOF/GOF variants, epilepsy onset is significantly later in GOF individuals (p = 0.008), whereas development before seizures, epilepsy outcome, and intellectual disability did not differ significantly. Comparing individuals with LOF and GOF variants, development before seizures, epilepsy onset, seizure outcome, and intellectual disability was not significantly different. Figure 2 illustrates the age at onset of epilepsy in the different subgroups.

Table 4. Phenotypic features of reported and novel patients, grouped according to known functional consequences on Kv1.2.

| n = 61 | LOF (n = 35) | GOF (n = 16) | GOF/LOF (n = 10) |
|--------|--------------|--------------|-----------------|
| Variants | Pro405Leu (16) | Arg297Gln (14) | Thr374Ala (7) |
| | Arg294His (9) | Glu157Lys (1) | Leu290Arg (1) |
| | Met255_Ile257del (7) | Leu298Phe (1) | Leu293His (1) |
| | Gln213 * (1) | | Leu328Val (1) |
| | Ile263Thr (1) | | |
| | Gly398Cys (1) | | |
| Development before seizure onset | normal (29/34) | normal (9/12) | normal (3/8) |
| | impaired (5/34) | impaired (3/12) | impaired (5/8) |
| Epilepsy onset age mean/median (SD) (months) | early childhood 17.4/8.75 (SD 31.2) (1 outlier with 156 m) | infantile or early childhood 11.6/9.5 (SD 8.6) (1 outlier with 18 m) | neonatal or early infantile 3.1/0.5 (SD 5.6) (1 outlier with 18 m) |
| Seizure types | focal only (5/30) | focal only (0/13) | focal only (5/10) |
| | generalized only (14/30) | generalized only (9/13) | generalized only (3/10) |
| | both (11/30) | both (4/15) | both (2/10) |
| Febrile seizures | yes (13/27) | yes (5/12) | yes (1/9) |
| | no (14/27) | no (7/12) | no (8/9) |
**Table 4. Cont.**

|                          | n = 61 | LOF (n = 35) | GOF (n = 16) | GOF/LOF (n = 10) |
|--------------------------|--------|--------------|--------------|------------------|
| Seizure outcome          |        |              |              |                  |
| never seizures           |        |              |              |                  |
| seizure-free             | (5/32) |              |              |                  |
| uncontrolled             | (14/32)|              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (9/35) |              |              |                  |
| mild                     | (9/35) |              |              |                  |
| moderate                 | (12/33)|              |              |                  |
| severe                   | (5/35) |              |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (18/28)|              |              |                  |
| tremor                   | (7/28) |              |              |                  |
| spasticity               | (6/28) |              |              |                  |
| episodic ataxia          | (6/28) |              |              |                  |
| CSWS                     | (9/20) |              | (0/11)       | (0/7)            |
| cMRI                     |        |              |              |                  |
| normal                   | (20/26)|              |              |                  |
| hippocampal sclerosis    | (2/26) |              |              |                  |
| DNET (1/26)              |        |              |              |                  |
| uncontrolled             | (4/26) |              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (0/14) |              |              |                  |
| mild                     | (3/14) |              |              |                  |
| moderate                 | (7/14) |              |              |                  |
| severe                   | (4/14) |              |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (16/16)|              |              |                  |
| tremor                   | (7/16) |              |              |                  |
| spasticity               | (0/16) |              |              |                  |
| spasticity               | (4/7)  |              |              |                  |
| CSWS                     | (9/20) |              | (0/11)       | (0/7)            |
| cMRI                     |        |              |              |                  |
| normal                   | (20/26)|              |              |                  |
| cerebellar atrophy       | (2/26) |              |              |                  |
| hippocampal sclerosis    | (2/26) |              |              |                  |
| DNET (1/26)              |        |              |              |                  |
| uncontrolled             | (4/26) |              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (5/14) |              |              |                  |
| cerebellar atrophy       | (8/14) |              |              |                  |
| subcortical white matter lesions | (1/14) |                  |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (4/4)  |              |              |                  |
| tremor                   | (1/5)  |              |              |                  |
| CSWS                     | (9/20) |              | (0/11)       | (0/7)            |
| cMRI                     |        |              |              |                  |
| normal                   | (20/26)|              |              |                  |
| cerebellar atrophy       | (5/10) |              |              |                  |
| DNET (1/26)              |        |              |              |                  |
| uncontrolled             | (4/26) |              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (5/14) |              |              |                  |
| cerebellar atrophy       | (8/14) |              |              |                  |
| subcortical white matter lesions | (1/14) |                  |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (4/4)  |              |              |                  |
| tremor                   | (1/5)  |              |              |                  |
| CSWS                     | (9/20) |              | (0/11)       | (0/7)            |
| cMRI                     |        |              |              |                  |
| normal                   | (20/26)|              |              |                  |
| cerebral atrophy         | (5/10) |              |              |                  |
| DNET (1/26)              |        |              |              |                  |
| uncontrolled             | (4/26) |              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (5/14) |              |              |                  |
| cerebellar atrophy       | (8/14) |              |              |                  |
| subcortical white matter lesions | (1/14) |                  |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (4/4)  |              |              |                  |
| tremor                   | (1/5)  |              |              |                  |
| CSWS                     | (9/20) |              | (0/11)       | (0/7)            |
| cMRI                     |        |              |              |                  |
| normal                   | (20/26)|              |              |                  |
| cerebral atrophy         | (5/10) |              |              |                  |
| DNET (1/26)              |        |              |              |                  |
| uncontrolled             | (4/26) |              |              |                  |
| Intellectual disability  |        |              |              |                  |
| normal                   | (5/14) |              |              |                  |
| cerebellar atrophy       | (8/14) |              |              |                  |
| subcortical white matter lesions | (1/14) |                  |              |                  |
| Movement disorders       |        |              |              |                  |
| ataxia                   | (4/4)  |              |              |                  |
| tremor                   | (1/5)  |              |              |                  |

The number of cases with specific clinical features is stated in relation to number of cases with available information concerning this feature. Responsive to treatment was defined as reported significant reduction of seizures. CSWS: continuous spikes and waves during slow sleep. DNET: dysembryoplastic neuroectodermal tumor. P: patient, m: months; ** p.(Arg294His); *** p.(Met255_Ile257del); ## due to neonatal epilepsy onset, cMRI was performed in first months of life.

**Figure 2.** Time-to-Event Curve. Percentage and age of first seizures of the functional subgroups LOF (blue), GOF (orange), and LOF/GOF (red).
2.4. Prediction of Functional Relevance of KCNA2 Variants

To evaluate the likelihood of pathogenic variant effects, we combined the distribution of known pathogenic and benign variants with computational pathogenicity scores for all biologically possible missense variants of KCNA2. The REVEL meta-score combines variant annotations of 13 individual pathogenicity scores and showed high overall performance in the discrimination of pathogenic and benign variants in large clinical datasets [42,43]. High REVEL scores overlap with areas of pathogenic variant enrichment in KCNA2 (Figure 3). Several peaks, corresponding to the voltage sensing domain (S4), the pore-loop (S5-S6) and the ion conducting pore with the gating mechanism (S5 and S6), were identified and are supported by similar tendencies in the evaluation of further established pathogenicity scores, such as CADD, M-CAP, PolyPhen, and SIFT (Figure S1). The density of putatively benign variants from the gnomAD database (green) shows enrichment at the less conserved N- and C-termini. In one specific region within S5, putatively benign variants are enriched, mainly being the result of tolerated changes at position Ala329.

**Figure 3.** Distribution of pathogenic and benign (tolerated) KCNA2 variants along the primary structure. (A) Density of pathogenic variants reported in Pubmed, HGMD, and ClinVar (red). (B) Linearized KCNA2 protein model including cytoplasmic (orange) as well as transmembrane and pore (green) domains. The amino acid position and description of previously published variants and variants reported here are highlighted in red (top) and violet (bottom), respectively. (C) Density of tolerated variants reported in gnomAD (light green). (D) Polynomial regression model of the REVEL ensemble pathogenicity score for all possible missense variants according to their position in the linearized Kvak1.2 protein. Enrichment of disease-associated variants can be observed in the transmembrane domains S4–6 and the pore loop. Distribution of pathogenic compared to benign variants is mainly reciprocal. REVEL scores approximately recapitulate pathogenic variant distribution.
3. Discussion

Recently, different neurological disorders, including epilepsy syndromes, ataxia, and hereditary spastic paraplegia were associated to Kv1.2 channel dysfunction. In this study, we present additional patients with known and novel KCNA2 variants. By analyzing phenotypic, functional, and genetic data from all published reports and novel cases, we refine and further delineate phenotypic and functional subgroups. Overall, the most prevalent manifestation was early-onset developmental and epileptic encephalopathy in combination with inconstant movement and motor disorders, mainly ataxia. Similar to other disorders related to voltage-gated ion channel genes (e.g., KCNA1, KCNQ2), a continuous spectrum from mild to severe neurologic manifestations and paroxysmal movement disorders can be delineated [44,45]. By comparing phenotypic characteristics from patients with functional data on mutational effects, carriers of variants leading to complex and mixed channel dysfunction that are associated with a gain and loss of potassium conductance more often show early developmental abnormalities and an earlier onset of epilepsy compared to patients with pure loss-of-function or pure gain-of-function variants, respectively.

3.1. Novel Cases of KCNA2 Variants and Clinical Presentation

We here report seven children with three known pathogenic variants and two novel variants in KCNA2. The variant p.(Tyr417Cys) was identified in a three-year-old boy (#1) with benign epilepsy of infancy (BFIS) and normal development. No other variants in known genes for BFIS were identified. The variant was inherited from an unaffected father. It is classified as a variant of unknown significance (VUS) according to the American College of Medical Genetics and Genomics (ACMG) (PM2, PP2, PP3) [46]. This variant is located at the cytosolic border of S6 in a region enriched for pathogenic variation and is predicted as damaging (Figure 3D, Table S1). The amino acid Tyr417 is spared from variation in the gnomAD database. Previous functional investigations of the homologous amino acid exchange in drosophila p.(Tyr485Cys) have shown that cysteine replacement of tyrosine at this position leads to a slight reduction of single channel conductance (γ), an increased deactivation rate, and a small decrease in the time constant for “ON gating currents” [47,48]. The clinical phenotype with self-limiting infantile-onset seizures in this boy is partially overlapping with the mild end of KCNA2-related epilepsy. Therefore, a role of the specific KCNA2 variant p.Tyr417Cys in benign infantile epilepsy (BFIS) appears possible, with a reduced penetrance, similar to other known genetic causes of infantile seizures such as PRRT2 [49], SCN2A [50], and SCN8A [51]. The novel variant p.(Pro407Ala) was found in a three-year-old girl (#2) with neonatal-onset developmental and epileptic encephalopathy and profound intellectual disability (ID). The variant occurred de novo and has not been described before. It is absent from controls in the gnomAD database and predicted as damaging. According to ACMG criteria, this variant is likely pathogenic (PM6, PM2, PP2, PP3) [46]. The variant leads to an exchange from proline to alanine at position 407 within a region that is enriched for pathogenic variants. It disrupts the highly conserved proline(405)–valine(406)–proline(407) (PVP) motif, which is essential for channel gating. Variants affecting prolines in the PVP motif and in closely related residues have been identified in KCNA2- and recently in KCNA1-associated early-onset epileptic encephalopathy [16,23,36,39,52]. Previous in vitro data of p.(Pro407Ala) in the Shaker Kv- channel suggested a non-conducting mutant channel as the underlying dysfunction [53]. This novel variant underlines the importance of the PVP motif regarding channel function.

The variant p.(Pro405Leu) affects the first proline of the PVP motif. We report two additional children with infantile-onset epilepsy and prolonged febrile seizures, harboring this recurrent variant. One of the two children had moderate intellectual disability, while the other one was described as normally developed. The mean age at seizure onset in all reported individuals with p.(Pro405Leu) was 9 months, and the main seizure types included focal and generalized seizures as well as febrile seizures. Continuous spikes and waves during sleep (CSWS) were reported in 8/13 individuals [13,16,23,34,37,38]. While
both our cases with p.(Pro405Leu) show sleep-activated spikes, CSWS was incomplete or unilateral, reflecting a milder epilepsy syndrome and suggesting interindividual variability.

We identified the variant p.(Arg297Gln) in a 9-year-old male patient (#5) with infantile onset epileptic encephalopathy and ataxia, showing significant overlap to previously reported individuals with this GOF variant, who constantly developed ataxia [3,13,14,16,24–29].

In twins, one boy and one girl (#6 and #7), we identified the recurrent variant c.881G>A; p.(Arg294His), which was described previously in families with hereditary spastic paraplegia [15,20]. Similar to family 3 from Helbig et al., the presenting symptom in both children was epilepsy with different focal and generalized seizure patterns, including absences and status epilepticus. While previous reports showed spastic paraplegia (6/7 individuals) and ataxia (4/7 individuals) as prominent manifestations, we here present two additional cases with seizures that included tonic–clonic and absence seizures in both children [15]. Interestingly, ataxia was present in the boy only, and ataxia was markedly worsened when valproate was temporarily applied, resembling absence epilepsy with ataxia (AEA) due to loss-of-function mutations in CACNA1A [54]. Similar to previous AEA families, intrafamilial variability was present, as the girl showed isolated seizures with age-appropriate cognitive development, the boy had a severe complex developmental disorder, and the father did not show neurologic symptoms. The further family history revealed a sister of the unaffected father who had intellectual disability and an unspecified movement disorder. The mother of the father (grandmother of the reported twins) had a progressive gait disorder from advanced age resembling spastic paraplegia. Unfortunately, genetic testing was not available.

3.2. Functional Classification and Phenotypic Spectrum of Published KCNA2 Variants

Previously, three distinct subgroups of KCNA2 variants with a genotype–phenotype correlation based on the electrophysiological channel properties were suggested [16]. We here analyze all available clinical reports and accordingly are able to group cases into these functional subgroups (LOF, GOF, and LOF/GOF). We show significant differences between subgroups regarding development before seizure onset, age at seizure onset, seizure outcome (seizure freedom), and intellectual disability. The combined dysfunctional effects of LOF/GOF variants are leading to more severe phenotypes compared to simple LOF or GOF variants. However, isolated LOF or GOF effects on Kv1.2 both lead to epileptic encephalopathy as well. Recently, Shore et al. (2020) provided data, showing how GOF variants can lead to epilepsy [55]. By expressing known epilepsy-causing KCNT1-gain-of-function variants in excitatory and inhibitory neurons, they were able to demonstrate specific mutational effects affecting inhibitory neurons only, especially interneurons with fast-spiking activity, promoting network hyperexcitability and hypersynchronicity. Cell-type-specific functional changes from distinct variants might also explain the more severe epilepsy course in children carrying variants with mixed LOF and GOF effects. It can be hypothesized that specific effects dominate in different neuronal subpopulations, leading to an impaired GABAergic response from interneurons on one side and to impaired glutamatergic transmission in excitatory neurons on the other side, affecting different inhibitory and excitatory networks. Interestingly, the homologous shaker mutation of the LOF variant p.(Arg294His) was shown to lead to proton currents in addition to the pure loss-of-Kv1.2 function when expressed in Xenopus laevis oocytes [15,56]. These effects are difficult to assess by most in vitro models, but in vivo neuron-subtype-specific dysfunctional effects with a loss of net potassium currents and additional a gain-of function from leaky proton currents might explain that the children described here exhibit focal and generalized absence seizures, which were previously attributed to gain-of-function effects in Kv1.2.

Apart from the electrophysiological classification of variants, which allows assigning some phenotypic features, recurrent variants in each functional subgroup show distinct variant-specific characteristics. Individuals with the variant p.(Pro405Leu) are more likely to have febrile seizures and CSWS than other individuals in the LOF subgroup. Individuals
with the variant p.(Arg294His) developed spastic paraplegia and ataxia as prominent manifestations. Seizures were described only in two previously reported cases [15] and in the two individuals reported here. Five individuals with the variant p.(Met255_Ile257del) presented with episodic ataxia, normal intellectual abilities and self-limited epilepsy, forming another distinct phenotype. In the GOF subgroup, apart from two individuals, all carried the recurrent variant p.(Arg297Gln). Therefore, characteristics of this subgroup are largely based on this variant. In the LOF/GOF subgroup, all but one individual with the variant p.(Thr374Ala) (n = 7) had neonatal refractory epilepsy. All showed severe intellectual disability, and in four of seven individuals, spastic cerebral palsy was reported (see Table S2: Summary of clinical data).

3.3. Prediction of Functional Relevance and Modelling of KCNA2 Variants

By combining the distribution of known pathogenic and benign variants with prediction scores for all possible missense variants, we further define protein regions with enrichment of pathogenic variants and highly predicted mutational effects, such as the voltage-sensing domain, the pore-loop, and the pore-forming domains. Both novel variants described here are affecting residues within these regions. Homology modeling of p.(Pro407Ala) and p.(Pro417Tyr) suggests effects on protein stability and protein structure of Kᵥ1.2 (Figure 1). Importantly, we here complement the phenotypes associated with variants in both prolines of the PVP motif that similar to KCNA1 are linked to severe early onset developmental and epileptic encephalopathy [52].

4. Materials and Methods

4.1. Database Research

Reports and entries of KCNA2 variants containing clinical and/or genetic data were identified using PubMed, Human Gene Mutation Database (HGMD), and ClinVar (Figure 4). PubMed literature research was performed using the keywords “KCNA2” and “voltage-gated potassium channel Kᵥ1.2”. ClinVar database entries were selected for variants classified as “pathogenic” or “likely pathogenic”. Reported variants were checked for duplicate mentions. Data acquisition was finished 30 April 2020. In addition, we collected clinical and genetic data from seven previously unpublished cases from European epilepsy centers with putatively causative variants in KCNA2. After the exclusion of one individual with a paternally inherited variant of uncertain significance (VUS) and all individuals without sufficient clinical information (37 ClinVar, 8 HGMD/Pubmed), 76 individuals were included into further statistical analyses (Figure 4).

Individuals were classified according to functional consequences of the mutated Kᵥ1.2 channel when functional data from in vitro analysis were available. Quantitative variables are illustrated by sample size, mean, and standard deviation. Statistical comparisons between means of two cohorts were performed with Welch’s two-sample t-test. Frequencies of descriptive variables are depicted with number, sample size, and percentages. Statistical comparisons of the frequency of descriptive variables between cohorts were conducted using the two-tailed Fisher’s exact test.
3.3. Prediction of Functional Relevance and Modelling of KCNA2 Variants

Importantly, we here complement the phenotypes associated with variants of Health, ClinVar: Clinically Relevant Sequence Variations database. HGMD: Human Gene Mutation Database, PubMed: public medicine database of the National Institutes of Health, ClinVar: Clinically Relevant Sequence Variations database.

4.2. Computational Pathogenicity Analysis and 3D Protein Structure Modeling

To visualize differences in variant distribution between affected individuals and unaffected controls, we compiled all currently known pathogenic and benign KCNA2 variants and their respective allele count using the databases PubMed, HGMD, ClinVar, and gnomAD. gnomAD variants referring to the canonical Ensembl transcript ENST00000485317.1 were selected by the categories “Missense” and “pLOF” (excluding frameshift variants). Variants were standardized to the NM_004974.3 transcript of the GRCh37/hg19 human reference genome using the Mutalyzer Nomenclature Checker web tool [57]. Additionally, all biologically possible missense variants of the KCNA2 coding sequence were computed and translated to the corresponding genomic position. Subsequently, established variant effect prediction (VEP) scores (REVEL, CADD, MetaLR, MetaSVM, M-CAP, PolyPhen-2, SIFT) were annotated using the VEP web tool of Ensembl Release 101 (http://grch37.ensembl.org/Tools/VEP, accessed on 18 January 2021; versions: dbNSFP v. 4.1a, REVEL v. 3.5a, CADD v. 1.6, M-CAP v. 1.3, PolyPhen-2 v. 2.2.2, SIFT v. 5.2.2) in order to evaluate the likelihood of pathogenic variant effects [58–65]. Resulting VEP scores of the canonical Ensembl feature and variant distributions were plotted along the primary structure of the Kᵥ1.2 protein using the geom_smooth and geom_density function, respectively, of the ggplot2 library in RStudio (v. 1.2.5042; RStudio, Inc., Boston, MA, USA) [66]. The REVEL meta-score demonstrated high overall performance regarding discrimination between pathogenic and benign single nucleotide variants in large clinical variant datasets [43]. Therefore, the REVEL score is primarily used in this study to assess the pathogenicity of variants. A complementary synopsis of all annotated VEP score results is depicted in Supplementary Figure S1.

Localization and structural consequence of the identified KCNA2 missense variants p.(Pro405Leu), p.(Pro407Ala), and p.(Tyr417Cys) in the quaternary protein structure were analyzed and visualized using PyMol (v. 2.5.0a; Schrödinger, LLC, New York, NY, USA) installed through Anaconda (v. 2020.11 with Python 3.8.5; Anaconda Inc., New York, NY, USA) and the existing PDB template 3LUT (chain B: α-subunit) of rat Kᵥ1.2.
5. Limitations

Due to limited and heterogeneous quality of data in publications, phenotypic features might not have been completely accessible. Therefore, the number of patients with available information is specified with each clinical feature. Due to differing age at imaging, the detectability of cerebellar changes might vary between reports. Despite the reasonable ability of the software programs to predict pathogenicity, they still cannot discriminate among functional LOF, GOF, and LOF/GOF-type variants. This is a critical limitation of computed predictions of variant effects in clinical practice and for genetic counseling. Furthermore, some recurrent variants represent a significant proportion of the cohort and variant-specific effects may dominate the phenotypic presentation of the whole functional subgroup.

6. Conclusions

Our study provides further insights into the clinical spectrum, genotype–phenotype correlations, variability, and predicted functional impact of KCNA2 variants. The location of variants reported here highlights the importance of the PVP motif in transmembrane domain S6 as a mutational hotspot. A novel case of self-limited infantile seizures suggests a continuous clinical spectrum of KCNA2-related disorders. The prediction of functional relevance of variants allowed us to identify hotspots of functional impact and recurrent mutations.

Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/1422-0067/22/6/2824/s1, Figure S1: synopsis of all annotated variant effect prediction (VEP) scores REVEL, CADD, MetaLR, MetaSVM, M-CAP, PolyPhen-2, SIFT. Table S1: Variant effect prediction scores. Table S2: Summary of clinical data.

Author Contributions: Conceptualization, J.H.D. and S.S.; methodology, J.S., S.S.; software, H.B.; validation, J.H.D., S.S., and J.S.; formal analysis, J.H.D. and J.S.; investigation, J.J., K.A.K., T.B., T.D., G.C.K., H.B., G.R.; resources, S.S., S.K., G.F.H.; data curation, J.H.D.; writing—original draft preparation, J.H.D.; writing—review and editing, J.J., K.A.K., T.B., T.D., G.C.K., H.B., G.R., S.K., G.F.H., J.R.L., S.S.; visualization, J.S.; supervision, S.S., G.F.H.; project administration, S.K.; funding acquisition, S.S. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded by the Dietmar-Hopp Foundation (Grant 1DH1813319 to Steffen Syrbe). Julian Schröter and Heiko Brennenstuhl receive support by the Physician Scientist Program at Ruprecht Karls University Heidelberg, Faculty of Medicine.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of the University of Heidelberg (S-318/2018). All individuals or their legal guardians gave their informed consent for data sharing and genetic testing.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Kuo, M.M.; Haynes, W.J.; Loukin, S.H.; Kung, C.; Saimi, Y. Prokaryotic K(+) channels: From crystal structures to diversity. FEMS Microbiol. Rev. 2005, 29, 961–985. [CrossRef]
2. Strong, M.; Chandy, K.G.; Gutman, G.A. Molecular evolution of voltage-sensitive ion channel genes: On the origins of electrical excitability. Mol. Biol. Evol. 1993, 10, 221–242. [CrossRef] [PubMed]
3. Corbett, M.A.; Bellows, S.T.; Li, M.; Carroll, R.; Micallef, S.; Carvill, G.L.; Myers, C.T.; Howell, K.B.; Maljevic, S.; Lerche, H.; et al. Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology 2016, 87, 1975–1984. [CrossRef]
4. Gu, C.; Jan, Y.N.; Jan, L.Y. A conserved domain in axonal targeting of Kv1 (Shaker) voltage-gated potassium channels. Science 2003, 301, 646–649. [CrossRef]
28. Ngo, K.J.; Rexach, J.E.; Lee, H.; Petty, L.E.; Perlman, S.; Valera, J.M.; Deignan, J.L.; Mao, Y.; Aker, M.; Posey, J.E.; et al. A diagnostic ceiling for exome sequencing in cerebellar ataxia and related neurological disorders. *Hum. Mutat.* 2020, 41, 487–501. [CrossRef] [PubMed]

29. Schwarz, N.; Uysal, B.; Rosa, F.; Loffler, H.; Mau-Holzmann, U.A.; Liebau, S.; Lerche, H. Establishment of a human induced pluripotent stem cell (iPSC) line (HIHDNEi002-A) from a patient with developmental and epileptic encephalopathy carrying a KCNA2 (p.Arg297Gln) mutation. *Stem Cell Res*. 2019, 37, 101445. [CrossRef]

30. Fernandez-Marmiesse, A.; Rocca, I.; Diaz-Flores, F.; Cantarini, V.; Perez-Poyato, M.S.; Fontalba, A.; Laranjeira, F.; Quintans, S.; Moldovan, O.; Felgueroso, B.; et al. Rare Variants in 48 Genes Account for 42% of Cases of Epilepsy With or Without Neurodevelopmental Delay in 246 Pediatric Patients. *Front. Neurosci.* 2019, 13, 1135. [CrossRef]

31. Parrini, E.; Marini, C.; Mei, D.; Galuppi, A.; Cellini, E.; Pucatti, D.; Chiti, L.; Rutigliano, D.; Blancini, C.; Virdo, S.; et al. Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes. *Hum. Mutat.* 2018, 39, 216–225. [CrossRef] [PubMed]

32. Schwarz, N.; Uysal, B.; Rosa, F.; Loffler, H.; Mau-Holzmann, U.A.; Liebau, S.; Lerche, H. Generation of an induced pluripotent stem cell (iPSC) line from a patient with developmental and epileptic encephalopathy carrying a KCNA2 (p.Leu328Val) mutation. *Stem Cell Res*. 2018, 33, 6–9. [CrossRef]

33. Uysal, B.; Loffler, H.; Rosa, F.; Lerche, H.; Schwarz, N. Generation of an induced pluripotent stem cell (iPSC) line (HIHDNEi003-A) from a patient with developmental and epileptic encephalopathy carrying a KCNA2 (pThr374Ala) mutation. *Stem Cell Res*. 2019, 40, 101543. [CrossRef]

34. Gong, P.; Xue, J.; Xiao, X.R.; Zhang, Y.H.; Yang, Z.X. [Genotype and phenotype of children with KCNA2 gene related developmental and epileptic encephalopathy]. *Zhonghua Er Ke Za Zhi* 2020, 58, 35–40. [CrossRef] [PubMed]

35. Hundallah, K.; Alenizi, A.; AlHashem, A.; Tabarki, B. Severe early-onset epileptic encephalopathy due to mutations in the KCNQ2 gene. *Epilepsia* 2019, 60, 1833–1836. [CrossRef]

36. Zhou, P.; He, N.; Zhang, J.W.; Lin, Z.J.; Wang, J.; Yan, L.M.; Meng, H.; Tang, B.; Li, B.M.; Liu, X.R.; et al. Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies. *Genes Brain Behav.* 2018, 17, e12456. [CrossRef]

37. Miao, P.; Feng, J.; Guo, Y.; Wang, J.; Xu, X.; Wang, Y.; Li, Y.; Gao, L.; Zheng, C.; Cheng, H. Genotype and phenotype analysis using an epilepsy-associated gene panel in Chinese pediatric epilepsy patients. *Clin. Genet.* 2018, 94, 512–520. [CrossRef] [PubMed]

38. Monies, D.; Abouelhoda, M.; AlSayed, M.; Alhashan, Z.; Atolabi, M.; Kayrali, H.; Al-Owain, M.; Shah, A.; Rahbenei, Z.; Al-Muhaizea, M.A.; et al. The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. *Hum. Genet.* 2017, 136, 921–939. [CrossRef]

39. Allou, L.; Julia, S.; Amsallem, D.; El Chehadeh, S.; Lambert, L.; Thevenon, J.; Duffourd, Y.; Sauzier, A.; Bouquet, P.; Pere, S.; et al. Rett-like phenotypes: Expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease. *Clin. Genet.* 2017, 91, 431–440. [CrossRef]

40. Lal, D.; Ruppert, A.K.; Trucks, H.; Schulz, H.; de Kovel, C.G.; Kastelein-Nolst Trenite, D.; Sonsma, A.C.; Koeleman, B.P.; Lindhout, D.; Weber, Y.G.; et al. Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies. *PloS Genet.* 2015, 11, e1005226. [CrossRef]

41. Riazuddin, S.; Hussain, M.; Razzaq, A.; Iqbal, Z.; Shahzad, M.; Polla, D.L.; Song, Y.; van Beusekom, E.; Khan, A.A.; Tomas-Roca, L.; et al. Exome sequencing of Pakistani consanguineous families identifies 30 novel candidate genes for recessive intellectual disability. *Mol. Psychiatry* 2017, 22, 1604–1614. [CrossRef]

42. Gunnig, A.C.; Fryer, V.; Fasham, J.; Crosby, A.H.; Ellard, S.; Baple, E.L.; Wright, C.F. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. *J. Med. Genet.* 2020, 107003. [CrossRef] [PubMed]

43. Li, J.; Zhao, T.; Zhang, Y.; Zhang, K.; Shi, L.; Chen, Y.; Wang, X.; Sun, Z. Performance evaluation of pathogenicity-computation methods for missense variants. *Nucleic Acids Res.* 2018, 46, 7793–7804. [CrossRef] [PubMed]

44. Kato, M.; Yamagata, T.; Kubota, M.; Arai, H.; Yamashita, S.; Nakagawa, T.; Fujii, T.; Sugai, K.; Imai, K.; Uster, T.; et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. *Epilepsia* 2013, 54, 1288–1297. [CrossRef] [PubMed]

45. Paulhus, K.; Ammerman, L.; Glasscock, E. Clinical Spectrum of KCNA1 Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity. *Int. J. Mol. Sci.* 2020, 21, 2802. [CrossRef] [PubMed]

46. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 2015, 17, 405–424. [CrossRef]

47. Ding, S.; Horn, R. Tail end of the s6 segment: Role in permeation in Shaker potassium channels. *J. Gen. Physiol.* 2002, 120, 87–97. [CrossRef]

48. Ding, S.; Horn, R. Effect of S6 tail mutations on charge movement in Shaker potassium channels. *Biophys. J.* 2003, 84, 295–305. [CrossRef]

49. Doring, J.H.; Saffari, A.; Bast, T.; Brockmann, K.; Ehrhardt, L.; Fazeli, W.; Janzarik, W.G.; Kluger, G.; Muhle, H.; Moller, R.S.; et al. The Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurological Disorders in Childhood. *Biomedicines* 2020, 8, 456. [CrossRef] [PubMed]

50. Herlenius, E.; Heron, S.E.; Grinton, B.E.; Keay, D.; Scheffer, I.E.; Mulley, J.C.; Berkovic, S.F. SCN2A mutations and benign familial neonatal-infantile seizures: The phenotypic spectrum. *Epilepsia* 2007, 48, 1138–1142. [CrossRef] [PubMed]
51. Gardella, E.; Becker, F.; Moller, R.S.; Schubert, J.; Lemke, J.R.; Larsen, L.H.; Eiberg, H.; Nothnagel, M.; Thiele, H.; Altmuller, J.; et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. *Ann. Neurol.* 2016, 79, 428–436. [CrossRef]

52. Rogers, A.; Golumbek, P.; Cellini, E.; Doccini, V.; Guerrini, R.; Wallgren-Pettersson, C.; Thuresson, A.C.; Gurnett, C.A. De novo KCNA1 variants in the PVP motif cause infantile encephalopathy and cognitive impairment similar to recurrent KCNA2 variants. *Am. J. Med. Genet. A* 2018, 176, 1748–1752. [CrossRef]

53. Hackos, D.H.; Chang, T.H.; Swartz, K.J. Scanning the intracellular S6 activation gate in the shaker K+ channel. *J. Gen. Physiol.* 2002, 119, 521–532. [CrossRef]

54. Imbrici, P.; Jaffe, S.L.; Eunson, L.H.; Davies, N.P.; Herd, C.; Robertson, R.; Kullmann, D.M.; Hanna, M.G. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. *Brain* 2004, 127, 2682–2692. [CrossRef]

55. Shore, A.N.; Colombo, S.; Tobin, W.F.; Petri, S.; Cullen, E.R.; Dominguez, S.; Bostick, C.D.; Beaumont, M.A.; Williams, D.; Khodagholy, D.; et al. Reduced GABAergic Neuron Excitability, Altered Synaptic Connectivity, and Seizures in a KCNT1 Gain-of-Function Mouse Model of Childhood Epilepsy. *Cell Rep.* 2020, 33, 108303. [CrossRef] [PubMed]

56. Starace, D.M.; Bezanilla, F. A proton pore in a potassium channel voltage sensor reveals a focused electric field. *Nature* 2004, 427, 548–553. [CrossRef] [PubMed]

57. Wildeman, M.; van Ophuizen, E.; den Dunnen, J.T.; Taschner, P.E. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. *Hum. Mutat.* 2008, 29, 6–13. [CrossRef]

58. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerassimova, A.; Bork, P.; Kondrashov, A.S.; Sunyaev, S.R. A method and server for predicting damaging missense mutations. *Nat. Methods* 2010, 7, 248–249. [CrossRef]

59. Dong, C.; Wei, P.; Jian, X.; Gibbs, R.; Boerwinkle, E.; Wang, K.; Liu, X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. *Hum. Mol. Genet.* 2015, 24, 2125–2137. [CrossRef] [PubMed]

60. Ioannidis, N.M.; Rothstein, J.H.; Pejaver, V.; Middha, S.; McDonnell, S.K.; Baheti, S.; Musolf, A.; Li, Q.; Holzinger, E.; Karyadi, D.; et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am. J. Hum. Genet.* 2016, 99, 877–885. [CrossRef] [PubMed]

61. Jagadeesh, K.A.; Wenger, A.M.; Berger, M.J.; Guturu, H.; Stenson, P.D.; Cooper, D.N.; Bernstein, J.A.; Bejerano, G. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat. Genet.* 2016, 48, 1581–1586. [CrossRef] [PubMed]

62. Liu, X.; Wu, C.; Li, C.; Boerwinkle, E. dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs. *Hum. Mutat.* 2016, 37, 235–241. [CrossRef] [PubMed]

63. Rentzsch, P.; Witten, D.; Cooper, G.M.; Shendure, J.; Kircher, M. CADD: Predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 2019, 47, D886–D894. [CrossRef] [PubMed]

64. Sim, N.L.; Kumar, P.; Hu, J.; Henikoff, S.; Schneider, G.; Ng, P.C. SIFT web server: Predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res.* 2012, 40, W452–W457. [CrossRef] [PubMed]

65. Yates, A.D.; Achuthan, P.; Akanni, W.; Allen, J.; Allen, J.; Alvarez-Jarreta, J.; Amode, M.R.; Armean, I.M.; Azov, A.G.; Bennett, R.; et al. Ensembl 2020. *Nucleic Acids Res.* 2020, 48, D682–D688. [CrossRef] [PubMed]

66. Hebebrand, M.; Huffmeier, U.; Trollmann, R.; Hehr, U.; Uebe, S.; Ekici, A.B.; Kraus, C.; Krumbiegel, M.; Reis, A.; Thiel, C.T.; et al. The mutational and phenotypic spectrum of TUBA1A-associated tubulinopathy. *Orphanet. J. Rare Dis.* 2019, 14, 38. [CrossRef]